

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 224 861 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(43) Date of publication:

24.07.2002 Bulletin 2002/30

(21) Application number: 00964699.3

(22) Date of filing: 05.10.2000

(51) Int Cl.7: **A01K 67/027**, A61K 45/00,

A61P 3/04, A61P 25/20,

A61P 37/08, A61P 43/00,

C12N 15/52, G01N 33/15,

G01N 33/50

(86) International application number:

PCT/JP00/06963

(87) International publication number:

WO 01/24627 (12.04.2001 Gazette 2001/15)

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

(30) Priority: 05.10.1999 JP 28481099

02.06.2000 JP 2000166726

(71) Applicants:

- Japan Science and Technology Corporation
Kawaguchi-shi, Saitama 332-0012 (JP)
- Osaka Bioscience Institute
Suita-shi, Osaka 565-0874 (JP)
- ORIENTAL YEAST CO., LTD.
Tokyo 174-8505 (JP)

(72) Inventors:

- URADE, Y., 706, Towacitycoop, 440, Konishi-cho
Kyoto-shi, Kyoto 604-0000 (JP)
- FUJITANI, Yasushi
Sakai-shi, Osaka 592-0898 (JP)
- KITAYAMA, Hiroaki
Kyoto-shi, Kyoto 610-1103 (JP)
- HAYASHI, Naoki
Yokohama-shi, Kanagawa 245-0018 (JP)

(74) Representative: Dzilewska, Hanna Eva

Frank B. Dehn & Co.,
European Patent Attorneys,
179 Queen Victoria Street
London EC4V 4EL (GB)

(54) **ANIMAL WITH THE MASS EXPRESSION OF HUMAN GENE AND TEST METHOD BY USING THE ANIMAL**

(57) The present application provides a human gene over-expressing animal, which is a non-human animal carrying a human hematopoietic prostaglandin D₂ synthase gene in its somatic cell chromosome and expressing a large amount of human prostaglandin D₂ synthase, wherein the animal is one obtained through ontogenesis of a totipotency cell of a non-human animal

or offspring of the obtained animal, and the totipotency cell is introduced with said synthase gene. The present application also provides a method of using the transgenic animal for testing *in vivo* activity of a candidate for anti-allergy medicines, sleep-controlling substances and candidates for anti-obesity.

EP 1 224 861 A1

Printed by Jouve, 75001 PARIS (FR)

BEST AVAILABLE COPY

Description

Technical Field

[0001] The invention of this application relates to a human gene over-expressing animal, and to various test methods using the animal. More precisely, the invention of this application relates to a non-human transgenic animal which carries, in its somatic cell chromosome, a gene encoding human PGD synthase (H-PGDS), an enzyme for synthesizing prostaglandin D₂ (PGD₂) that is one causal substance for allergy and sleep induction, and which can produce a large amount of PGD₂ through over expression of the enzyme. The invention also relates to methods of using the animal for testing active ingredients of medicines for preventing and curing allergic diseases, sleep disorders, life habit-caused disorders such as obesity.

Background Art

[0002] H-PGDS (Biochem. Biophys. Acta 575:43-51, 1979; J. Biol. Chem. 262:3820-3825, 1987; Cell 90: 1085-1095, 1997) is an enzyme having the function of producing an endogenous substance, prostaglandin D₂ (PGD₂; Prostaglandins Leukot. Essent. Fatty Acids, 37: 219-234, 1989; FASEB J. 5:2575-2581, 1991; J. Lipid Mediat. Cell Signalling, 14:71-82, 1996) that has various physiological activities, and it is expressed in immune-cytes and genital organs (J. Immunol. 143:2982-2989, 1989; J. Biol. Chem. 270:3239-3246, 1995). It is known that PGD₂ produced from mast cells by the action of H-PGDS is involved in exacerbation of inflammations, and its degraded substance, 15d-PGJ₂ (15-deoxy- Δ 12,14-PGJ₂) is a differentiation factor for adipose cell (Cell, 83:803-812 & 813-819, 1995).

[0003] H-PGDS is expressed in mast cell and antigen-presenting cell (J. Immunol. 143:2982-2989, 1989; J. Biol. Chem. 270:3239-3246, 1995), and participates in production of PGD₂ in allergic inflammation. It is known that thus produced PGD₂ causes bronchoconstriction and vasodilation and involves in aggravation of allergies.

[0004] Of all endogenous sleep-inducing substances that have been clarified up to the present, PGD₂ has the most potent sleep-inducing activity. It is reported that in human patients suffering from trypanosome-infected African sleeping sickness, the PGD₂ level in the cerebrospinal fluid increases 100 to 1,000-fold with aggravation of the disease condition (Trans Royal Soc. Trop. Med. Hyg. 84:795-799, 1990). In addition, it is known that in pathologic deep sleep observed in systemic mastocytosis patients, the blood PGD₂ level also increases 150-fold (New Engl. J. Med. 303:1400-1404, 1980), and the important role of PGD₂ in pathologic sleep is suggested.

[0005] As mentioned above, it is suggested that PGD₂ and H-PGDS producing PGD₂ closely correlate to vari-

ous physiological functions of individuals, and may be a potential cause of human diseases. However, no animal model system has as yet been established that enables the study under the controlled condition how the over expression of H-PGDS will act on animal.

[0006] The invention of this application has been made in consideration of the above-mentioned situation, and its object is to provide a non-human animal that genetically expresses a large amount of H-PGDS. Another object of this application is to provide methods of using the animal for testing the effectiveness of preventing or curing substances for various diseases caused by the over expression of H-PGDS in the animal.

Disclosure of The Invention

[0007] This application provides inventions of the following (1) to (5):

(1) A human gene over-expressing animal, which is a non-human animal carrying a human hematopoietic prostaglandin D₂ synthase gene in its somatic cell chromosome and expressing a large amount of human prostaglandin D₂ synthase, wherein the animal is one obtained through ontogenesis of a totipotency cell of a non-human animal or offspring of the obtained animal, and the totipotency cell is introduced with said synthase gene.

(2) The human gene over-expressing animal of the invention (1), wherein the non-human animal is a mouse.

(3) A method for testing *in vivo* activity of a candidate for the anti-allergy medicines, which comprises administering the candidate to the human gene over-expressing animal of the invention (1) or (2), and measuring allergic reactions of the animal to thereby evaluate the activity of the candidate.

(4) A method for testing *in vivo* activity of sleep-controlling substances, which comprises administering a candidate for the substances to the human gene over-expressing animal of the invention (1) or (2), and measuring sleep condition of the animal to thereby evaluate the activity of the candidate.

(5) A method for testing *in vivo* activity of a differentiation-controlling substance for mast cell and adipose cell, which comprises administering a candidate for the substance to the human gene over-expressing animal of the invention (1) or (2), and measuring the obesity condition of the animal to thereby evaluate the activity of the candidate.

Brief Description of The Drawings

[0008]

Fig. 1 is a schematic view showing the construction of the transfer vector used in producing a transgenic mouse of this invention.

Fig. 2 shows the results of H-PGDS Northern blot analysis of mRNA extracted from various organs of three lines of transgenic mice and from those of a wild-type mouse.

Fig. 3 shows the results of H-PGDS Northern blot analysis of mRNA extracted from all organs of a transgenic mouse.

Fig. 4 shows the results of H-PGDS enzyme activity data obtained by using fractionations of proteins extracted from various organs of three lines of transgenic mice and from those of a wild-type mouse.

Fig. 5 shows the data of inflammatory cells counted in the wash of air vesicles of antigen-immunized transgenic mice and wild-type mice after exposure to physiological saline or antigen.

Fig. 6 shows the data of spontaneous locomotor for 12-hours of transgenic and wild-type mice with intraperitoneal administration of lipopolysaccharide (20 mg/kg).

Fig. 7 shows the data (A) of body weight change of transgenic (TG) and wild-type (WT) mice fed with a high-fat food, and the data (B) of white adipose tissue weight of the mice fed with a normal food or a high-fat food.

The Best Mode for Carrying Out The Invention

[0009] For the transgene, human H-PGDS gene, its cDNA can be used. The H-PGDS cDNA may be prepared according to a method that comprises synthesizing an oligonucleotide based on the base sequence of a desired part of a known rat cDNA sequence (Cell 90: 1085-1095, 1997; GenBank Accession No. D82071) or human cDNA sequence (Eur. J. Biochem. 267: 3315-3322, 2000; GenBank Accession No. NM014485), and using it as a probe to screen a human cDNA library, or an RT-PCR method that comprises synthesizing oligonucleotides capable of hybridizing sequences at both ends of the intended cDNA fragment, and using it as primers to prepare the H-PGDS cDNA from an mRNA isolated from human cells.

[0010] The transgene has a promoter sequence or an enhancer sequence linked thereto, which is for controlling the over expression of the gene. The promoter sequence or the enhancer sequence are not specifically

defined, for which, for example, suitably used is a promoter region or an enhancer region of a gene capable of being highly expressed in various organs of the transgenic animal.

[0011] The human gene over-expressing animal of the invention (1) can be produced in accordance with a known method of producing transgenic animals (for example, Proc. Natl. Acad. Sci. USA 77:7380-7384, 1980). Specifically, the transgene is introduced into totipotency cell of a non-human animal, the cell is ontogenized into individuals, and those carrying the transgene in the genome of the somatic cells thereof are selected. The thus-selected individuals are of the intended transgenic animal. From the technical viewpoint, animals of any and every species may be employed for the non-human animal for use herein, but mice are the best for it, since a large number of inbred lines have been available and, in addition, the technique of fertilized egg incubation and external fertilization thereof has been established in the art. Of mice, the totipotency cell to be introduced with the gene may be those of fertilized eggs or early embryos. For gene introduction into cultured cell, DNA micro-injection method is the best in view of the yield of the transgenic animals and of the transgene transfer efficiency to the next generations.

[0012] The fertilized eggs into which the gene has been injected are implanted into the oviduct of a surrogate mother, in which the eggs are ontogenized into individuals, and the individual animals are born from it and then are bred by a foster mother. Thus bred, DNA is extracted out of the animal at a part of its body (the tip of the tail), and subjected to Southern blotting analysis or PCR to confirm the presence of the transgene. The individual animal in which the presence of the transgene has been confirmed is the founder, and the transgene is transferred to 50 % of the offspring of the founder. In that manner, wild-type or variant animals can be produced efficiently.

[0013] The thus-produced transgenic animal produces excess H-PGDS, and therefore can be the best model for investigating the physiological activities of PGD₂.

[0014] The invention (3) of this application is a method for testing *in vivo* activity of a candidate for anti-allergy medicines, which comprises administering the candidate to the human gene over-expressing animal of the invention (1), and measuring the allergic reaction in the animal to thereby evaluate the activity of the candidate. Specifically, the transgenic animal of the invention (1) carries a large amount of H-PGDS and produces a large amount of PGD₂, and therefore sensitively reacts with various types of allergens. Accordingly, for example, when a certain allergen is previously administered to the animal, a candidate for anti-allergy medicine is then thereto, and the systemic allergic reaction of the animal is measured, then the pharmacological activity of the candidate can be evaluated.

[0015] The invention (4) of this application is a method for testing *in vivo* activity of a sleep-controlling sub-

stance, which comprises administering a candidate for the substance to the human gene over-expressing animal of the invention (1), and measuring the sleep condition of the animal to thereby evaluate the activity of the candidate. Specifically, the transgenic animal of the invention (1) carries a large amount of H-PGDS and produces a large amount of PGD₂, and therefore its sleep control is disordered due to the strong sleep-inducing action of PGD₂. Accordingly, for example, when a candidate for sleep control (for example, a substance having the ability to sustain vigilance) is administered to the animal and the awake/sleep condition of the animal is measured, and then the pharmacological activity of the candidate can be evaluated. The awake/sleep condition of the animal can be determined by measuring the locomotor activity thereof or measuring the food intake or water intake thereof, or by measuring the physiological parameters such as electroencepharogram or electromyogram thereof.

[0016] The invention (5) of this application is a method for testing *in vivo* activity of a candidate for anti-obesity medicine, which comprises administering a candidate for anti-obesity medicine to the human gene over-expressing animal of above (1), and measuring the degree of obesity of the animal (e.g., body weight, fatty tissue weight) to thereby evaluate the activity of the candidate. Specifically, the transgenic animal of the invention (1) carries a large amount of H-PGDS and produces a large amount of PGD₂, and therefore produces a large amount of 15d-PGJ₂ that involves in increase of the body weight or fatty tissue weight in the animal, and, as a result, the animal gets fat. Accordingly, for example, when a candidate for anti-obesity is administered to the animal and the degree of the obesity of the animal is measured, and then the pharmacological activity of the candidate can be evaluated.

Examples

[0017] The invention of this application is described in more detail and concretely with reference to the following Examples, which, however, are not intended to restrict the scope of the invention of this application.

Example 1

(1) Production of Transgenic Mice:

[0018] From the cDNA library prepared from mRNA of human cells, human H-PGDS cDNA was cloned by using rat H-PGDS cDNA as a probe.

[0019] Next, the human H-PGDS cDNA was inserted and linked into a cloning site (SalI/NotI) of the vector (pCAGGS) to construct a transfer vector. Fig. 1 shows the construction of the transgene in the transfer vector. As in Fig. 1, the transgene has a CMV enhancer and a chicken β -actin promoter upstream the H-PGDS cDNA, and when introduced into a mouse chromosome, it ex-

presses a large amount of H-PGDS mRNA owing to the action of the enhancer and the promoter.

[0020] The transfer vector was introduced into fertilized eggs of an FVB mouse through microinjection. The gene-introduced fertilized eggs were then implanted into the oviduct of a surrogate mother in an ordinary manner, in which those are ontogenized into individuals, and the individuals were then born.

[0021] DNA was extracted from the tail of each of the thus-obtained mouse individuals, and it was analyzed through Southern blotting analysis using a probe that had been synthesized on the basis of the sequence of the transgene. Based on the data of the thus-analyzed DNA, transgenic mice were selected. Three independent lines of transgenic mice were thus established, which differ from each other in the degree of H-PGDS expression therein. The data are as in Fig. 2.

(2) Investigation of Gene Expression in Transgenic Mice:

[0022] Systemic expressions of the transgene of the transgenic mice were examined with Northern blot analysis. As a result, it was confirmed that in S55 mouse, the H-PGDS gene was expressed to a high level in the skeletal muscle, the heart, the lung, the large intestine and the liver. The data are as in Fig. 3.

(3) Investigation of PGD Enzyme Activity in Transgenic Mice:

[0023] Using a substrate PGH₂, the PGD enzyme activity in various organs of the transgenic mice was determined. In the transgenic mice, the enzyme activity significantly increased in various organs. The three lines of transgenic mice were compared with each other in point of the enzyme activity thereof. The enzyme activity increase in these was in an order of S55 > S41 > S66. The data are as in Fig. 4.

Example 2

[0024] As a human asthma model, the transgenic mice obtained in Example 1 were analyzed in antigen-induced lung inflammation model.

[0025] After antigen challenge, the invasion of eosinophilic leukocytes into the lung of the transgenic mice significantly increased, as compared with that into the lung of the wild-type mice. The data are as in Fig. 5.

[0026] The result as above confirms that the transgenic mice of this invention are useful as a model animal for clarifying the mechanism of allergosis and are effective for the system of screening novel anti-allergy substances.

Example 3

[0027] A lipopolysaccharide was intraperitoneally ad-

ministered to the transgenic mice obtained in Example 1, and the inflamed mice in narcolepsy were analyzed.

[0028] Concretely, a high-concentration (20 mg/kg) lipopolysaccharide was administered to the transgenic mice, and the spontaneous locomotor of each mouse was observed. As a result, the spontaneous locomotor of the transgenic mice significantly lowered as compared with that of the wild-type mice. This suggests that the sleep time of the transgenic mice increased. The data are as in Fig. 6.

[0029] The result as above confirms that the transgenic mice of this invention are useful as a model animal for clarifying the mechanism of sleep induction and are effective for the system of screening novel substances of controlling sleep-awake rhythm.

Example 4

[0030] The transgenic mice obtained in Example 1 and wild-type mice were loaded with a high-fat food, and analyzed for the obesity progress.

[0031] Concretely, the mice were loaded with a high-fat food for 6 weeks, and their body weight increase was observed. As compared with that of the wild-type mice, the body weight of the transgenic mice significantly increased. In addition, the white adipose tissue weight of the transgenic mice also significantly increased. The data are as in Fig. 7.

Industrial Applicability

[0032] As described in detail hereinabove, the invention provides a transgenic animal that expresses a large amount of H-PGDS and therefore produces a large amount of PGD₂. The animal promotes the development of medicines for various human diseases.

Claims

1. A human gene over-expressing animal, which is a non-human animal carrying a human hematopoietic prostaglandin D₂ synthase gene in its somatic cell chromosome and expressing a large amount of human prostaglandin D₂ synthase, wherein the animal is one obtained through ontogenesis of a totipotency cell of a non-human animal or offspring of the obtained animal, and the totipotency cell is introduced with said synthase gene.
2. The human gene over-expressing animal of claim 1, wherein the non-human animal is a mouse.
3. A method for testing *in vivo* activity of a candidate for the anti-allergy medicines, which comprises administering the candidate to the human gene over-expressing animal of claim 1 or 2, and measuring allergic reactions of the animal to thereby evaluate

the activity of the candidate.

4. A method for testing *in vivo* activity of sleep-controlling substances, which comprises administering a candidate for the substances to the human gene over-expressing animal of claim 1 or 2, and measuring sleep condition of the animal to thereby evaluate the activity of the candidate.
5. A method for testing *in vivo* activity of a differentiation-controlling substance for mast cell and adipose cell, which comprises administering a candidate for the substance to the human gene over-expressing animal of claim 1 or 2, and measuring the obesity condition of the animal to thereby evaluate the activity of the candidate.

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6





Fig. 7



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/06963

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl. ⁷ A01K67/027, A61K45/00, A61P3/04, A61P25/20, A61P37/08, A61P43/00, C12N15/52, G01N33/15, G01N33/50 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl. ⁷ A01K67/027, A61K45/00, A61P3/04, A61P25/20, A61P37/08, A61P43/00, C12N15/52, G01N33/15, G01N33/50 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Jitsuyo Shinan Koho 1922-1996 Toroku Jitsuyo Shinan Koho 1994-2000 Kokai Jitsuyo Shinan Koho 1971-2000 Jitsuyo Shinan Toroku Koho 1996-2000 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DIALOG (BIOSIS) JOIS (JICST FILE)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	JP, 11-332417, A (Japan Science and Technology Corp.), 07 December, 1999 (07.12.99), Full text; Figs. 1 to 9 (Family: none)	1-5
Y	JP, 9-322773, A (Osaka Bio Science Kenkyusho), 16 December, 1997 (16.12.97), Full text; Figs. 1 to 11 (Family: none)	1-5
A	Cell, Vol.90, No.6, 1085-1095, (1997)	1-5
Y	Cell, Vol.83, No.5, 803-812, (1995)	1,2,5
Y	Cell, Vol.83, No.5, 813-819, (1995)	1,2,5
P, X P, Y	Proc. Natl. Acad. Sci. USA, Vol.97, No.9, 4903-4907, (25.04.00)	1,2,4 3,5
Y	Saibou Kougaku, Vol.17, No.5, 707-713, (1998)	1-5
Y	Shinyaku to Rinshou, Vol.45, No.9, 1647-1650, (1995)	1-3
Y	Tanpakushitsu, Kakusan, Kouso, Vol.45, No.6, 1072-1076,	1-3
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family		
Date of the actual completion of the international search 26 December, 2000 (26.12.00)		Date of mailing of the international search report 16 January, 2001 (16.01.01)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.		Authorized officer Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/06963

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	(2000)	
Y	Isotope News, No.522, 6-11, (1997)	1-5
Y	Masui, Vol.47, special issue, S11-S17, (1998)	1,2,4
Y	Medical Immunology, Vol.15, No.2, 217-220, (1988)	1-5
Y	Tanpakushitsu Kakusan Kousei, Vol.40, No.14, 2001-2007, (1995)	1-5
P,X P,Y	Bio Science to Industry, Vol.58, No.9, 643-644, (01.09.00)	1,2,4 3,5
X Y	Nippon Rinsho, Vol.56, No.2, 488-492, (1998)	1,2,4 3,5

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.